$MDCO Breaks Out, Expect Further Gains

$MDCO has been having a banner year with the stock up over 200%. We think this rally still has legs and that $MDCO is going to keep climbing after Monday's huge breakout. Here's a look at what drove Monday's breakout.

Results from a Phase 3 clinical trial, ORION-9, evaluating the effect of The Medicines Company's (MDCO +2.3%) inclisiran on reducing "bad" cholesterol (LDL-C) in patients with familial hypercholesterolemia ( FH ), an inherited condition characterized by abnormally high levels of cholesterol in the blood, showed a treatment benefit. The data were presented at the American Heart Association Scientific Sessions in Philadelphia.

The study met the primary endpoints of percent change in LDL-C from baseline to day 510 (50% reduction) versus placebo and time-averaged percent change (45% reduction) in LDL-C after day 90 up to day 510 versus control. Both values were statistically significant.

No new safety signals were observed.

The results will be submitted for presentation in a peer-reviewed medical journal. The company expects to file a U.S. marketing application this quarter and one in Europe next quarter.

The company will host a conference call today at 12 noon ET to discuss the results from ORION-9 and ORION-10.

In other news, there are also rumblings this morning that Novartis (NYSE:NVS) may be circling.

As always, use protective stops and trade with caution.

Good luck to all!
Trade closed: target reached: Gains of 42% in a week.

Congrats to all who participated!

To receive our alerts via email and SMS, join Insider Financial for Free at

We are not financial advisors. Always conduct your own research and read our full disclaimer at